comparemela.com

Biol Med News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Breath biomarkers enhance microbiome research

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

The primary endpoint in this study was met for the 4 mg baricitinib group. However, key secondary endpoints were not. No new safety signals were observed.

vimarsana © 2020. All Rights Reserved.